Opinion|Videos|July 9, 2024
Examining Challenges with Drug Switching and Step Therapy in MS Treatment
Key opinion leaders discuss the challenges associated with step therapy requirements after initially selecting a drug class, the patient factors considered when deciding to switch a patient with non-relapsing secondary progressive multiple sclerosis to a different therapy, and whether payers commonly employ step therapy between different drug classes.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Do you ever encounter challenges with step therapy requirements after initially selecting a drug class?
- What patient factors do you consider when deciding to switch a patient to a different therapy in patients diagnosed with non-relapsing secondary progressive multiple sclerosis?
- Are step therapies typically used for drugs within the same class, or do payers typically use step therapy between different classes of drugs?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
ATTR-CM Incidence, Prevalence Rose Sharply in the US
3
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
4
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
5